The risks for disease progression and death were lower for patients with stage 3b or higher CKD receiving GLP-1 ... RA on kidney function in patients with moderate to advanced CKD, although ...

More clinical trials on the direct and indirect effects of GLP-1s and their mechanisms of action are needed. As the body of research expands on the potential of glucagon-like peptide-1 receptor ...

Are compounded GLP-1s safe? Dr Ro breaks down the risks, FDA concerns, and telemedicine's role in prescribing these meds — what physicians must know to protect their patients.

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy.

Over a median of 3.68 years, adults with type 2 diabetes who added a GLP-1 agent to their treatment ... were likely driven by two main mechanisms of action -- the first being a reduction in ...

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications for weight loss are significantly transforming the fiel ...

or it had a different mechanism of action. “There’s a lot of hype and excitement around GLP-1 and like medications,” Youssef. “And the thing I want to see is long-term safety data.

Truveta’s groundbreaking study analyzing real-world use of GLP-1 receptor agonist (GLP-1 RA) therapies in adults with overweight or obesity has published in JAMA Network Open, offering critical ...

Jan. 31, 2025 (GLOBE NEWSWIRE) -- Truveta’s groundbreaking study analyzing real-world use of GLP-1 receptor agonist (GLP-1 RA) therapies in adults with overweight or obesity has published in JAMA ...